{"analyses":[{"ciLowerLimit":"0.88","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.43","groupDescription":"Stratified analysis","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3425","paramType":"Hazard Ratio (HR)","paramValue":"1.12","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.92","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.48","groupDescription":"Unstratified Analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2166","paramType":"Hazard Ratio (HR)","paramValue":"1.16","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.08","upperLimit":"28.29","value":"22.80"},{"groupId":"OG001","lowerLimit":"16.59","upperLimit":"22.05","value":"19.19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"431"}],"units":"Participants"}],"description":"OS is defined as the time from randomization to death from any cause. Results from a pre-specified interim analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"MEDIAN","populationDescription":"ITT population: all randomized participants, whether or not the assigned study treatment was received","reportingStatus":"POSTED","timeFrame":"From Day 1 to death from any cause, assessed up to end of study (up to approximately 36 months)","title":"Overall Survival (OS) in the ITT Population","type":"SECONDARY","unitOfMeasure":"Months"}